"Amphotericin B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.
| Descriptor ID |
D000666
|
| MeSH Number(s) |
D02.540.576.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Amphotericin B".
Below are MeSH descriptors whose meaning is more specific than "Amphotericin B".
This graph shows the total number of publications written about "Amphotericin B" by people in this website by year, and whether "Amphotericin B" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 2 | 3 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 4 | 5 |
| 2017 | 18 | 22 | 40 |
| 2018 | 10 | 20 | 30 |
| 2019 | 1 | 8 | 9 |
| 2020 | 0 | 3 | 3 |
| 2021 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Amphotericin B" by people in Profiles.
-
Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis/aspergillus tracheobronchitis. Crit Care. 2021 08 19; 25(1):298.
-
Palatal mucormycosis in a patient with SARS-CoV-2 infection. CMAJ. 2021 08 16; 193(32):E1254.
-
Voriconazole-Induced Hepatotoxicity Resolved after Switching to Amphotericin B in Fusarium dimerum Central Line-Associated Bloodstream Infection. Am J Case Rep. 2021 Aug 10; 22:e932544.
-
Diabetes mellitus and Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): A wake-up call from Egypt. Diabetes Metab Syndr. 2021 Sep-Oct; 15(5):102195.
-
Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses. 2021 Oct; 64(10):1238-1252.
-
COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? BMJ Case Rep. 2021 Apr 27; 14(4).
-
The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses. 2021 Aug; 64(8):798-808.
-
Fatal disseminated aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus ochraceus. J Mycol Med. 2021 Jun; 31(2):101124.
-
Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now. 2021 Oct; 51(7):633-635.
-
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021 06; 21(6):e149-e162.